# International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer

> **NCT01252693** · PHASE2 · COMPLETED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 203 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Ozarelix
- **DRUG:** Goserelin

## Key facts

- **NCT ID:** NCT01252693
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2014-09
- **Final completion:** 2015-05
- **Target enrollment:** 203 (ACTUAL)
- **Last updated:** 2021-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01252693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01252693, "International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01252693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*